Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
24
×
life sciences
national blog main
new york blog main
new york top stories
24
×
national top stories
san francisco blog main
san francisco top stories
biotech
clinical trials
national
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
startups
cancer
novartis
eli lilly
investing
amgen
boston
ipo
biogen
bristol-myers squibb
What
new
24
×
drug
medicines
bio
fda
roundup
cancer
companies
drugs
medicine
approved
ipo
approval
biotech
deal
genetic
known
latest
life
research
science
therapeutics
wave
aims
big
brings
called
cholesterol
class
crispr
cut
depression
developing
disease
fast
gets
group
hasn’t
immunotherapy
isn’t
Language
unset
Current search:
new
×
" boston top stories "
×
" new york top stories "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Ireland to Sequence 400K Genomes With New Precision Medicine Effort
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?